These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33558360)

  • 1. Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption.
    Kårhus ML; Brønden A; Lyng Forman J; Haaber A; Vilsbøll T; Sonne DP; Knop FKK
    BMJ Open; 2021 Feb; 11(2):e044711. PubMed ID: 33558360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial.
    Kårhus ML; Brønden A; Forman JL; Haaber A; Knudsen E; Langholz E; Dragsted LO; Hansen SH; Krakauer M; Vilsbøll T; Sonne DP; Knop FK
    Lancet Gastroenterol Hepatol; 2022 Oct; 7(10):922-931. PubMed ID: 35868334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
    Gudbergsen H; Henriksen M; Wæhrens EE; Overgaard A; Bliddal H; Christensen R; Boesen MP; Knop FKK; Astrup A; Rasmussen MU; Bartholdy C; Daugaard C; Bartels EM; Ellegaard K; Heitmann BL; Kristensen LE
    BMJ Open; 2019 May; 9(5):e024065. PubMed ID: 31061017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial.
    Borup C; Vinter-Jensen L; Jørgensen SPG; Wildt S; Graff J; Gregersen T; Zaremba A; Borup Andersen T; Nøjgaard C; Timm HB; Rainteau D; Hansen SH; Rumessen JJ; Munck LK
    Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):321-331. PubMed ID: 36758570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colesevelam for the treatment of bile acid malabsorption-associated diarrhea in patients with Crohn's disease: a randomized, double-blind, placebo-controlled study.
    Beigel F; Teich N; Howaldt S; Lammert F; Maul J; Breiteneicher S; Rust C; Göke B; Brand S; Ochsenkühn T
    J Crohns Colitis; 2014 Nov; 8(11):1471-9. PubMed ID: 24953836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying bile acid malabsorption helps predict response and tailor sequestrant therapy.
    Orekoya O; McLaughlin J; Leitao E; Johns W; Lal S; Paine P
    Clin Med (Lond); 2015 Jun; 15(3):252-7. PubMed ID: 26031975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.
    Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU
    BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet.
    Jensen SBK; Lundgren JR; Janus C; Juhl CR; Olsen LM; Rosenkilde M; Holst JJ; Stallknecht BM; Madsbad S; Torekov SS
    BMJ Open; 2019 Nov; 9(11):e031431. PubMed ID: 31678947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Multicenter Prospective Study to Investigate the Diagnostic Accuracy of the SeHCAT Test in Measuring Bile Acid Malabsorption: Research Protocol.
    Reid F; Peacock J; Coker B; McMillan V; Lewis C; Keevil S; Sherwood R; Vivian G; Logan R; Summers J
    JMIR Res Protoc; 2016 Feb; 5(1):e13. PubMed ID: 26832436
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Mena Bares LM; Carmona Asenjo E; García Sánchez MV; Moreno Ortega E; Maza Muret FR; Guiote Moreno MV; Santos Bueno AM; Iglesias Flores E; Benítez Cantero JM; Vallejo Casas JA
    Rev Esp Med Nucl Imagen Mol; 2017; 36(1):37-47. PubMed ID: 27765536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study.
    Idorn T; Knop FK; Jørgensen M; Jensen T; Resuli M; Hansen PM; Christensen KB; Holst JJ; Hornum M; Feldt-Rasmussen B
    BMJ Open; 2013; 3(4):. PubMed ID: 23624993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial.
    Vijayvargiya P; Camilleri M; Carlson P; Nair A; Nord SL; Ryks M; Rhoten D; Burton D; Busciglio I; Lueke A; Harmsen WS; Donato LJ
    Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2962-2970.e6. PubMed ID: 32088296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and rationale for the randomised, double-blinded, placebo-controlled Liraglutide to Improve corONary haemodynamics during Exercise streSS (LIONESS) crossover study.
    Myat A; Arri S; Bhatt DL; Gersh BJ; Redwood SR; Marber MS
    Cardiovasc Diabetol; 2015 Feb; 14():27. PubMed ID: 25848859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion.
    Hansen M; Scheltema MJ; Sonne DP; Hansen JS; Sperling M; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2016 Jun; 18(6):571-80. PubMed ID: 26888164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome.
    Camilleri M; Acosta A; Busciglio I; Boldingh A; Dyer RB; Zinsmeister AR; Lueke A; Gray A; Donato LJ
    Aliment Pharmacol Ther; 2015 Mar; 41(5):438-48. PubMed ID: 25594801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire.
    Wedlake L; Thomas K; Lalji A; Anagnostopoulos C; Andreyev HJ
    Clin Ther; 2009 Nov; 31(11):2549-58. PubMed ID: 20109999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
    Ishøy PL; Knop FK; Broberg BV; Baandrup L; Fagerlund B; Jørgensen NR; Andersen UB; Rostrup E; Glenthøj BY; Ebdrup BH
    BMJ Open; 2014 Jan; 4(1):e004158. PubMed ID: 24401727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry).
    Sass MR; Danielsen AA; Köhler-Forsberg O; Storgaard H; Knop FK; Nielsen MØ; Sjödin AM; Mors O; Correll CU; Ekstrøm C; Vinberg M; Nielsen J; Vilsbøll T; Fink-Jensen A
    BMJ Open; 2023 Jan; 13(1):e068652. PubMed ID: 36720576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment.
    Barkun AN; Love J; Gould M; Pluta H; Steinhart H
    Can J Gastroenterol; 2013 Nov; 27(11):653-9. PubMed ID: 24199211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial.
    Foghsgaard S; Vedtofte L; Mathiesen ER; Svare JA; Gluud LL; Holst JJ; Damm P; Knop FK; Vilsbøll T
    BMJ Open; 2013 Oct; 3(10):e003834. PubMed ID: 24176797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.